摘要
用免疫比浊法测定52例冠心病患者及25例健康人的血清载脂蛋白A1、B100（apoA1、apoB100）浓度，并以发色底物法测定同样患者血浆组织型纤溶酶原激活剂（t－PA）及其抑制物-1即纤溶酶原激活抑制物-1（PAI－1）活性，结果显示急性心肌梗塞及不稳定型心绞痛组apoB100、PAI－1活性显著高于正常对照组，t－PA、apoA1显著低于正常对照组；apoB100与PAI－1活性呈显著正相关，apoA1与PAI－1活性在冠心病患者及健康对照组呈负相关。故认为，apoB100与PAI－1的活性相关，在冠状动脉痉挛和冠脉内血栓形成中可能起一定作用。
In this study, serum concentration of apoA1and apob100 of 52 cases of coronary heart disease (CHD) and 19 controls were measured by immunoturbidimetry assay. Meanwhile, plasma tissue plasminogen activator (t-PA) and plasrninogen activator inhibitor-1 (PAl-1 ) activities of all personswere determined by spectrophotometric assay. The results showed that the mean concentration of apoB100 and API-1 activity in acute myocardial infarction and unstable angina pectoris (UAP) was significantly higher than those of the control group ; the tPA activity and concentration of apoA1 were obviously lower than those of the controls; The concentration of apoB100 was positively correlated with PAI-1activity ; but apoA1 was opposite. According to these results, it is considerded that apoB100 is consistant with PAI-1 activity and apoB100 plays an important role in coronarv arterv SDasm and thrornbosis.
出处
《西安医科大学学报》
CSCD
1997年第4期447-449,共3页
Journal of Xi'an Medical University(Chinese)
关键词
冠心病
载脂蛋白
纤溶酶原激活剂
coronary heart disease
apolipoprotein A_1 (apoA_1 )
apolipoprotein B_(100)(apoB_(100))
